结外自然杀伤/T细胞淋巴瘤鼻型的治疗研究进展

Research progress in the treatment of extranodal natural killer/T-cell lymphoma-nasal type

结外自然杀伤(NK)/T细胞淋巴瘤鼻型(ENKTL)是一种侵袭性恶性肿瘤,多见于亚洲和南美洲人群。EB病毒(EBV)感染与ENKTL的发病和患者预后密切相关。NK细胞淋巴瘤预后指数-EB病毒(PINK-E)模型是目前临床上较实用的ENKTL患者预后评估模型。ENKTL的治疗方案包括放疗、含L-天冬酰胺酶的非蒽环类化疗、造血干细胞移植、靶向程序性细胞死亡蛋白-1/程序性细胞死亡蛋白-1配体(PD-1/PD-L1)轴治疗,已取得显著疗效。未来,新的治疗方案包括抗EBV治疗、信号通路治疗和表观遗传学治疗等具有极大治疗潜力,有待临床试验加以验证。

Extranodal natural killer(NK)/T-cell lymphoma-nasal type(ENKTL)is an aggressive malignant tumor,which is more common in Asian and South American populations.Epstein-Barr virus(EBV)infection is closely related to the pathogenesis and prognosis of ENKTL.Prognostic index of NK cell lymphoma(PINK)-E model is a practical clinical prognostic model for patients with ENKT.The treatment regimens of ENKTL including radiotherapy,non-anthracycline-containing chemotherapy with L-asparaginase,hematopoietic stem cell transplantation,and targeted programmed cell death protein-1/programmed cell death protein-ligand-1(PD-1/PD-L1)axis therapy,which have achieved remarkable efficacy.In the future,new therapeutic options including anti-EBV therapy,signal-pathway therapy and epigenetic therapy could have great therapeutic potential,and need to be verified in clinical trials.